Evolution and clinical translation of drug delivery nanomaterials

Citation data:

Nano Today, ISSN: 1748-0132, Vol: 15, Page: 91-106

Publication Year:
2017
Captures 8
Readers 8
Social Media 578
Shares, Likes & Comments 554
Tweets 24
DOI:
10.1016/j.nantod.2017.06.008
Author(s):
Shabir Hassan, Gyan Prakash, Ayca Bal Ozturk, Saghi Saghazadeh, Muhammad Farhan Sohail, Jungmok Seo, Mehmet Remzi Dokmeci, Yu Shrike Zhang, Ali Khademhosseini
Publisher(s):
Elsevier BV
Tags:
Biochemistry, Genetics and Molecular Biology, Medicine, Chemical Engineering, Engineering, Materials Science, Pharmacology, Toxicology and Pharmaceutics
Most Recent Tweet View All Tweets
review description
With the advent of technology, the role of nanomaterials in medicine has grown exponentially in the last few decades. The main advantage of such materials has been exploited in drug delivery applications, due to their effective targeting that in turn reduces systemic toxicity compared to the conventional routes of drug administration. Even though these materials offer broad flexibility based on targeting tissue, disease, and drug payload, the demand for more effective yet highly biocompatible nanomaterial-based drugs is increasing. While therapeutically improved and safe materials have been introduced in nanomedicine platforms, issues related to their degradation rate and bio-distribution still exist, thus making their successful translation to clinical application very challenging. Researchers are constantly improving upon novel nanomaterials that are safer and more effective not only as therapeutic agents but as diagnostic tools as well, making the research in the field of nanomedicine ever more fascinating. In this review, the stress has been made on the evolution of nanomaterials that are under different stages of clinical trials or have been approved by the United States Food and Drug Administration (FDA).

This review has 0 Wikipedia mention.